Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beauvechain – page 122

1 944 clinical trials in Beauvechain, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beauvechain at a glance
1 944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 944 trials in Beauvechain

Open in trial search

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Everolimus
  • Sponsor:Rayzebio Inc.

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

K-ras gene mutation+1

Not recruiting

Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:ETOP IBCSG Partners Foundation

Gastrooesophageal cancer+5

Not recruiting

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Phenylbutyrate
  • Sponsor:Amylyx Pharmaceuticals Inc.

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beauvechain

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management strategies in primary care settings. The studies examine optimal approaches for patients with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Strategies
  • Gastrointestinal Health Management
  • Primary Care Interventions

Investigations compare different therapeutic approaches, including on-demand medication use and alternative treatments, to improve long-term patient outcomes in acid-related disorders.

02 Primary Care Medicine

Studies evaluating the effectiveness of various medication discontinuation protocols for patients with chronic heartburn and related conditions. Research aims to establish optimal treatment pathways.

  • Medication Management
  • Patient-Centered Care
  • Treatment Optimization

The research explores alternative therapeutic options and their impact on patient well-being and quality of life.

03 Digestive Health

Clinical investigations examining the management of acid reflux and related conditions through various therapeutic approaches, including traditional and alternative treatment methods.

  • Symptom Management
  • Alternative Therapies
  • Long-term Care Strategies

Research focuses on developing evidence-based approaches for medication reduction while maintaining optimal symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.